Company news
Viatris Inc. (NASDAQ:VTRS) news
Viatris Inc. news releases on 6ix. Latest, Nov 7, 2022: Viatris Reports Strong Third Quarter 2022 Results
Press releases — page 4
Viatris Reports Strong Third Quarter 2022 Results
November 6, 2022
Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event
November 6, 2022
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
November 6, 2022
Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022
October 23, 2022
Viatris Named to Forbes' Annual List of the World's Best Employers for the Second Year in a Row
October 10, 2022
Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)
September 20, 2022
Viatris Inc. to Participate in BofA Global Research Global Healthcare Conference
September 5, 2022
Viatris Reports Strong Second Quarter 2022 Results
August 7, 2022
Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022
June 30, 2022
Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
May 19, 2022
Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals
May 15, 2022
Viatris Reports Strong First-Quarter 2022 Results
May 8, 2022
Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022
April 7, 2022
Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19
March 29, 2022
Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent
March 16, 2022
Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva
March 15, 2022
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfoli...
February 27, 2022
Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
February 3, 2022
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
February 2, 2022
Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend
January 5, 2022
Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations
December 28, 2021
Viatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results
December 16, 2021
Viatris Named by Newsweek as One of America's Most Responsible Companies
December 5, 2021
Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent
November 30, 2021
Viatris to Participate in Evercore ISI 4th Annual HealthCONx Conference
November 17, 2021
Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
November 15, 2021
Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Back" fund in Support of Housing Solutions for Veterans in Disaster-Impacted Communities
November 10, 2021
Viatris Reports Strong Third Quarter Results, Raises 2021 Financial Guidance and Announces Virtual Investor Event on January 7, 2022
November 7, 2021
Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary
October 19, 2021
Viatris Inc. to Release Third Quarter 2021 Financial Results on Nov. 8, 2021
October 12, 2021
Viatris Named Fifth on Fortune's Change the World List
October 10, 2021
Viatris Inc. to Participate in Citi's 16th Annual BioPharma Conference
August 29, 2021
Viatris Inc. to Participate in BofA Global Healthcare Conference
August 29, 2021
Viatris Reports Strong Second Quarter Results
August 8, 2021
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
July 27, 2021
Mylan Wins Dismissal of Kansas EpiPen® Direct Purchaser Case
July 26, 2021
Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021
July 7, 2021
Viatris Inc. to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
May 24, 2021
Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend
May 9, 2021
Viatris Inc. Releases Inaugural Sustainability Report, Reinforcing its Commitment to Better Health and Better Communities Worldwide
May 5, 2021
Viatris Inc. to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
April 29, 2021
Viatris Inc. to Participate in BofA Securities 2021 Health Care Conference
April 28, 2021
Viatris Inc. to Release First Quarter 2021 Financial Results on May 10, 2021
April 11, 2021
Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol
March 7, 2021
Viatris Inc. to Participate in Barclays Global Healthcare Conference
March 3, 2021
Viatris Inc. Hosts Inaugural Investor Day Outlining Unique and Differentiated Business Model, High-Quality Operational Platform, and Focus on CSR and Financial Commitments
February 28, 2021
Viatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments
February 21, 2021
Viatris Inc. to Hold Conference Call on Monday, Feb. 22, 2021, to Discuss 2021 Financial Guidance
February 8, 2021
Mylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi
December 17, 2020
Viatris Inc. Recommends Caution on TRC Capital Corp.'s Attempt to Acquire Shares at a Significant Discount via Mini-Tender Offer
December 14, 2020